

Freedom Of Information request 016377 – Drugs and patients treated

26/9/22

Information pulled from different databases

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below: Information from March 2022 to August 2022

- Revolade (eltrombopag) = 9
- Nplate (romiplostim) = 6
- Doptelet (avatrombopag) = 0
- Tavlesse (fostamatinib) = 0

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)? - The Pharmacy database does not drill down to drugs against patient disease, clinical coding would be able to give you numbers of patients with ITP if they were inpatients but the coding does not drill down to drugs patient was treated with.

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with: - see response to question 2  
rituximab  
mycophenolate mofetil  
surgery (splenectomy)

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

- The Trust is currently participating in the UK Adult ITP Registry which has 11 recruits. Recruitment will be coming to an end soon.

-----  
Q1. Does your trust treat myelofibrosis? = Yes

If not, which other trust do you refer these patients to? – N/A

Q2.

A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4). - see response to question 4

b) How many of these patients were above age 65? - see response to question 4

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib? – Not known

Q4.

A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? - Over a 3 year period the numbers are less than 5 so as per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the persons involved and in this instance the number is less than 5, Exemption Section 40(2) of the Freedom of Information Act is applied

b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with: - Not known, would have to check individual records to find this information and individual records are exempt under Exemption Act

- Hydroxyurea
- Fedratinib
- Received No Treatment

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

- The Trust participates in a number of myeloma trials, however non specifically for myelofibrosis

-----

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with: **NONE**

- Bevacizumab (Avastin)
- Dacarbazine (DTIC)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
- Ipilimumab (Yervoy)
- Vemurafenib (Zelboraf)
- Nivolumab (Opdivo)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Pembrolizumab (Keytruda)
- Vemurafenib + cobimetinib (Zelboraf + Cotellic)
- Dabrafenib + Trametinib (Tafinlar + Mekinist)
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following: - **NONE**

- Ipilimumab
  - Ipilimumab AND Nivolumab
  - Nivolumab
  - Pembrolizumab
  - Dabrafenib AND Trametinib
  - Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
  - Other active systemic anti-cancer therapy
  - Palliative care only
-

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib - 2
- Alectinib - 1
- Atezolizumab monotherapy - 4
- Atezolizumab in combination - 3
- Bevacizumab - 0
- Brigatinib - 0
- Capmatenib - 0
- Ceritinib - 0
- Crizotinib - 0
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy - 1
- Durvalumab - 1
- Erlotinib - 0
- Gefitinib - 0
- Gemcitabine - 0
- Nintedanib with Docetaxel - 0
- Nivolumab - 1
- Osimertinib - 5
- Paclitaxel - 0
- Pembrolizumab monotherapy - 12
- Pembrolizumab in combination - 15
- Pemetrexed with Carboplatin/Cisplatin - 12
- Tepotinib - 0
- Vinorelbine with Cisplatin/Carboplatin - 6
- Any other SACT - 11
- Palliative care only - cannot specify